Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables
- PMID: 21997685
- DOI: 10.1097/PAS.0b013e31822d63a7
Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables
Abstract
Gastrointestinal stromal tumor (GIST) natural history per se has not been extensively investigated yet, with most data being drawn from large studies with a relevant referral bias. Hence, the estimation of prognosis still remains a critical issue. We retrospectively evaluated 929 GISTs resected between 1980 and 2000 in 35 Italian institutions. A total of 526 patients were found to be suitable for refining risk assessment through the development of a survival nomogram. Median follow-up was 126 months. On testing for potential prognostic parameters, age, tumor site, size, and mitotic index proved to be predictors of OS on both univariable and multivariable Cox model analyses, whereas necrosis and cytonuclear atypia were significant on univariable analysis only. The discriminative ability of the model, including the parameters selected after a backward procedure (C=0.72), improved compared with the National Institutes of Health 2002 (C=0.64) and the National Comprehensive Cancer Network 2007 (C=0.63). On the basis of these data we developed a prognostic nomogram for survival that considers site, size, and mitotic index as continuous variables, providing estimates stratified for patients aged ≤65 and >65 years. This nomogram is a tool based on survival. It overcomes problems that result from artificial categorization of continuous variables. We believe that in the future this should also be attempted by nomograms based on the risk of relapse.
Similar articles
-
Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.Chin Med J (Engl). 2010 Jan 20;123(2):131-6. Chin Med J (Engl). 2010. PMID: 20137358
-
Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.J Clin Pathol. 2008 Jun;61(6):722-9. doi: 10.1136/jcp.2007.052225. Epub 2008 Apr 1. J Clin Pathol. 2008. PMID: 18381383
-
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.Eur J Surg Oncol. 2011 Oct;37(10):890-6. doi: 10.1016/j.ejso.2011.06.005. Epub 2011 Jul 7. Eur J Surg Oncol. 2011. PMID: 21737227
-
Gastrointestinal stromal tumors (GISTs): a pathology view point.J Med Assoc Thai. 2009 Jan;92(1):124-35. J Med Assoc Thai. 2009. PMID: 19260254 Review.
-
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.Lancet Oncol. 2012 Mar;13(3):265-74. doi: 10.1016/S1470-2045(11)70299-6. Epub 2011 Dec 6. Lancet Oncol. 2012. PMID: 22153892 Review.
Cited by
-
Update on Molecular Genetics of Gastrointestinal Stromal Tumors.Diagnostics (Basel). 2021 Jan 28;11(2):194. doi: 10.3390/diagnostics11020194. Diagnostics (Basel). 2021. PMID: 33525726 Free PMC article. Review.
-
Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review.Transl Oncol. 2020 Oct;13(10):100812. doi: 10.1016/j.tranon.2020.100812. Epub 2020 Jun 28. Transl Oncol. 2020. PMID: 32619820 Free PMC article. Review.
-
Perspectives on the evolving state of the art management of gastrointestinal stromal tumours.Transl Gastroenterol Hepatol. 2018 Apr 26;3:21. doi: 10.21037/tgh.2018.04.02. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 29780899 Free PMC article. Review.
-
Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts.EBioMedicine. 2020 Oct;60:103016. doi: 10.1016/j.ebiom.2020.103016. Epub 2020 Sep 25. EBioMedicine. 2020. PMID: 32980695 Free PMC article.
-
Adjuvant therapy of gastrointestinal stromal tumors (GIST).Curr Treat Options Oncol. 2012 Sep;13(3):277-84. doi: 10.1007/s11864-012-0198-0. Curr Treat Options Oncol. 2012. PMID: 22743760 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical